Trends in pharmacogenomics of drugs acting on hypertension

Pharmacological Research

Volumn 49, Issue 4, 2004, Pages 351-356

  Trotta, Roberto ^a,c   Donati, Maria Benedetta ^b   Iacoviello, Licia ^a,b  

^a Angela Valenti Lab Thromb P   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antihypertensive drugs; Hypertension; Pharmacogenetics; Polymorphisms

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ADDUCIN; ALPHA ADDUCIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; ARYLAMINE ACETYLTRANSFERASE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2D6; DEBRISOQUINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOSINOPRIL; HYDRALAZINE; IRBESARTAN; METHYLDOPA; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; GENE DELETION; GENE INSERTION; GENE LOCUS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; PHARMACOGENOMICS; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SIGNAL TRANSDUCTION; SODIUM RESTRICTION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE;

EID: 0842328714     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.07.018     Document Type: Article

References (76)

1. Motulsky A. Drug reactions, enzymes and biochemical genetics. J. Am. Med. Assoc. 165:1957;835-837.
2. Vogel F. Moderne probleme der humangenetik. Ergebn. Inn Med Kinderheilk. 12:1959;52-125.
3. Meyer U. Drugs in special patient groups: clinical importance of genetics in drug effects. In: Melmon K, Morelli H, Hoffman B, Nierenberg D, editors. Clinical pharmacology: basic principles in therapeutics. New York: McGraw-Hill, Inc.; 1992. p. 875-94.
4. Burt V.L., Whelton P., Roccella E.J., Brown C., Cutler J.A., Higgins M. et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 25:1995;305-313.
5. Sharma P., Fatibene J., Ferraro F., Jia H., Monteith S., Brown C.et al. A genome-wide search for susceptibility loci to human essential hypertension. Hypertension. 35:2000;1291-1296.
6. Lifton R.P. Molecular genetics of human blood pressure variation. Science. 272:1996;676-680.
7. Horan M.J., Mockrin S.C. Heterogeneity of hypertension. Am. J. Hypertens. 5:1992;110S-113S.
8. Hamet P., Pausava Z., Adarichev V., Adaricheva K., Tremblay J. Hypertension: genes and environment. J. Hypertens. 16:1998;397-418.
9. Sever P. The heterogeneity of hypertension: why doesn't every patient respond to every antihypertensive drug? J. Hum. Hypertens. 9(Suppl. 2):1995;S33-S36.
10. Niutta E., Cusi D., Colombo R., Pellizzoni M., Cesana B., Barlassina C. et al. Predicting interindividual variation in anti-hypertensive therapy: the role of sodium transport systems and renin. J. Hypertens. 6(Suppl. 4):1990;S53-S58.
11. Laragh J.H., Lamport B., Sealey J., Alderman M.H. Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension. 12:1988;223-226.
12. Menard J., Bellet M., Serrurier D. From the parallel group study to the crossover design, and from the group approach to the individual approach. Am. J. Hypertens. 3:1990;815-819.
13. Trotta R, De Luca N, Iovino G, Izzo R, Rozza F, Di Castelnuovo A, et al. Italian Heart J 2002;3(Suppl 7).
14. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.et al. The sequence of human genome. Science. 291:2001;1304-1351.
15. Zito F., Di Castelnuovo A., Amore C., D'Orazio A., Donati M.B., Iacoviello L. Bcl I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients. Arterioscler. Thromb. Vasc. Biol. 17:1997;3489-3494.
16. Iacoviello L., Di Castelnuovo A., De Knijff P., D'Orazio A., Amore C., Arboretti R.et al. Polimorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N. Engl. J. Med. 338:1998;79-85.
17. Materson B.J., Reda D.J., Cushman W.C., Massie B.M., Freis E.D., Kochar M.S.et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N. Engl. J. Med. 328:1993;914-921.
18. Weder A, Julius S. Pathophysiology of hypertension and treatment. In: Singh B, Vanhoutte P, Dzau V, Woosley R, editors. Cardiovascular pharmacology and therapeutics. New York: Churchill Livingstone Inc.; 1994. p. 861-83.
19. Hall W. Pharmacologic therapy of hypertension in blacks. J. Clin. Hypertens. 3:1987;108S-113S.
20. Jamerson K., De Quattro V. The impact of ethnicity on response to antihypertensive therapy. Am. J. Med. 101:1996;22S-32S.
21. Seedat Y. Varying responses to hypotensive agents in different racial groups: black versus white differences. J. Hypertens. 7:1989;515-518.
22. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-6.
23. Gonzales F.J., Skoda R.C., Kimura S., Umeno M., Zanger U.M., Nebert D.W.et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 331:1988;442-446.
24. Mahgoub A., Idle J.R., Dring L.G., Lancaster R., Smith R.L. Polymorphic hydroxylation of debrisoquine in man. Lancet. 2:1977;584-586.
25. Daly A., Brockmoller J., Broly F., Eichelbaum M., Evans W., Gonzales F. et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics. 6:1996;193-201.
26. Broly F., Gaedigk A., Heim M., Eichelbaum M., Morike K., Meyer U.A. Debrisoquine/sparteine hydroxylase genotype and phenotype. DNA Cell Biol. 10:1991;545-558.
27. Alvan G., von Bahr C., Seidman P., Sjoqvist F. High plasma concentrations of β-receptors blocking drugs and deficient debrisoquine hydroxylation. Lancet. 1:1982;333.
28. Dahl M.L., Johansson I., Palmertz M.P., Ingelman-Sundberg M., Sjoqvist F. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin. Pharmacol. Ther. 51:1992;12-17.
29. Kalow W., Otton S., Kadar D., Endrenyi L., Inaba T. Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals. Can. J. Physiol. Pharmacol. 58:1980;1142-1144.
30. Johansson I., Lundqvist E., Bertilsson I., Dahl M., Sjoqvist F.et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U.S.A. 90:1993;11825-11829.
31. Lennard M., Silas J., Freestone S., Ramsay L., Tucker G., Woods H. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N. Engl. J. Med. 307:1982;1558-1560.
32. Lennard M., Silas J., Freestone S., Trevethick J. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br. J. Clin. Pharmacol. 14:1982;301-303.
33. Shah R., Oates N., Idle J., Smith R. Beta-blockers and drug oxidation status. Lancet. 1:1982;508-509.
34. Dayer P., Balant L., Kupfer A., Courvoisier F., Fabre J. Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents. Eur. J. Clin. Pharmacol. 24:1983;797-799.
35. Silas J., Freeston S., Lennard M., Ramsay L. Chronic dosing comparison of three formulations of metoprolol and atenolol in hypertensive patients. Br. J. Clin. Pharmacol. 18:1984;270P.
36. Buchert E., Woosley R. Clinical implications of variable anti-arrhythmic drug metabolism. Pharmacogenetics. 2:1992;2-11.
37. Broly F., Marez D., Sabbagh N., Legrand M., Millecamps S., Lo Giudice J.et al. An efficient strategy for detection of know and new mutations of the CYP2D6 gene using single strand conformation polymorphisms analysis. Pharmacogenetics. 5:1995;373-384.
38. Franke S., Klawitz I., Schnakemberg E., Rommel B., van der Wen W., Bullerdick J.et al. Isolation and mapping of a cosmid clone containing the human NAT2 gene. Biochem. Biophys. Res. Commun. 199:1994;52-55.
39. Hickman D., Risch A., Buckie V., Spurr N., Jeremiah S., McCarthy A.et al. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem. J. 297:1994;441-445.
40. Dufour A., Knight R., Harris H. Genetics of isoniazid metabolism in Caucasian, Negro, and Japanese populations. Science. 145:1964;391.
41. Karim A., Elfellah M., Evans D. Human acetylator polymorphisms: estimates of allele frequency in Lybia and details of global distribution. J. Med. Genet. 18:1981;325-333.
42. Sunahara S., Motoyuki U., Ogawa M. Genetical and geographic studies on isoniazid inactivation. Science. 134:1961;1530.
43. Zacest R., Koch-Weser J. Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin. Pharmacol. Ther. 13:1972;420-425.
44. Jounela A., Pasanen M., Mattila M. Acetylator phenotype and the antihypertensive response to hydralazine. Acta Med. Scand. 197:1975;303-306.
45. Shepherd A., McNay J., Ludden T., Lin M., Musgrave G. Plasma concentration and acetylator phenotype determine response to oral hydralazine. Hypertension. 3:1981;580-585.
46. Perry H. Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am. J. Med. 54:1973;58-72.
47. Uetrecht J., Woosley R. Acetylator phenotype and lupus erythematosus. Clin. Pharmacokinet. 6:1981;118-134.
48. Batchelor J., Welsh K., Tinoco R., Dollery C., Hughes G., Bernstein R.et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet. 1:1980;1107-1109.
49. Dudley C., Keavney B., Casadei B., Conway J., Bird R., Ratcliff P. Prediction of patient response to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J. Hypertens. 14:1996;259-262.
50. Mayer G. ACE genotype and ACE inhibitor response in kidney disease: a perspective. Am. J. Kidney Dis. 40:2002;227-235.
51. Baudin B. Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations. Pharmacogenomics. 3:2002;65-73.
52. Hingorani A.D., Jia H., Stevens P., Hopper R., Dickerson J.E., Brown M.J. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J. Hypertens. 13:1995;1602-1609.
53. Stavroulakis G.A., Makris T.K., Krespi P.G., Hatzizacharias A.N., Gialeraki A.E., Anastasiadis G.et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc. Drugs Ther. 14:2000;427-432.
54. Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman K.P.et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J. Hpertens. 19:2001;1783-1787.
55. Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman P.et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J. Hypertens. 20:2002;657-663.
56. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322:1990;1561-1566.
57. Verdecchia P., Schillaci G., Borgioni C., Ciucci A., Gattobigio R., Zampi I.et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 97:1998;48-54.
58. Hughes C.A., Bennet V. Adducin: a physical model with implications for function in assembly of spectrin-actin complexes. J. Biol. Chem. 270:1995;18990-18996.
59. Matsuoka Y., Hughes C.A., Bennat V. Definition of the calmodulin-binding domain and sites of phosphorylation by protein kinase A and C. J. Biol. Chem. 271:1996;25157-25166.
60. Bianchi G., Tripodi G., Casari G., Salardi S., Barber B., Garcia R.et al. Two point mutations within the adducin gene are involved in blood pressure variation. Proc. Natl. Acad. Sci. U.S.A. 91:1994;3999-4003.
61. Tripodi G., Valtorta F., Torielli L., Chieregatti E., Salardi S., Trusolino S.et al. Hypertension-association point mutations in the adducin α and β subunits affect actin cytoskeleton and ion transport. J. Clin. Invest. 97:1996;2815-2822.
62. Cusi D., Barlassina C., Azzani T., Casari G., Citterio L., Devoto M.et al. Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet. 349:1997;1353-1357.
63. Glorioso N., Manunta P., Filigheddu F., Troffa C., Stella P., Barlassina C.et al. The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension. 34:1999;649-654.
64. Sciarrone M.T., Stella P., Barlassina C., Manunta P., Lanzani C., Bianchi G., Cusi D. ACE and α-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension. 41:2003;398-403.
65. Psaty B.M., Smith N.L., Heckbert S.R., Vos H.L., Lemaitre R.N., Reiner A.P.et al. Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA. 287:2002;1680-1689.
66. Hunt S.C., Cook N.R., Oberman A., Culter J.A., Hennekens C.H., Allender P.S.et al. Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension. Trials of hypertension prevention, phase II. Hypertension. 32:1998;393-401.
67. Poch E., Gonzales D., Giner V., Bragulat E., Coca A., de La Sierra A. Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphism. Hypertension. 38:2001;1204-1209.
68. Lifton R.P. Molecular genetics of human blood pressure variation. Science. 272:1996;676-680.
69. Ishikawa Y., Homcy C.J. The adenyl cyclases as integrators of transmembrane signal transduction. Circ. Res. 80:1997;297-304.
70. Yatani A., Brown A.M. Rapid β-adrenergic modulation of cardiac calcium channel currents by a fast G protein pathway. Science. 245:1989;71-74.
71. Yoshikawa H., Fukuda K., Wanaka Y., Kasamatsu K., Baba A., Nishio I.et al. Deficient activity of stimulatory nucleotide-binding regulatory protein in lymphocytes from patients with essential hypertension. Am. J. Hypertens. 7:1994;713-716.
72. Feldman R.D., Tan C.M., Chorazyczewski J. G protein alterations in hypertension and aging. Hypertension. 26:1995;725-732.
73. Feldman R.D., Lawton W.J., McArdle W.L. Low sodium diet corrects the defects in lymphocyte beta-adrenergic responsiveness in hypertensive subjects. J. Clin. Invest. 79:1987;290-294.
74. Jia H., Hingorani A.D., Shama P., Hopper R., Dickerson C., Trutwein D.et al. Association of the Gsα gene with essential hypertension and response to β-blockade. Hypertension. 34:1999;8-14.
75. Moskowitz D.W. From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. Diabetes Technol. Ther. 4:2002;519-532.
76. Hamet P. Genes and hypertension: where we are and where we should go. Clin. Exp. Hypertens. 21:1999;947-960.